ReviewCancer immunology research2019
Adoptive Immunotherapy with Antigen-Specific T Cells Expressing a Native TCR.
Review in Cancer immunology research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 31 citations in OpenAlex.
- Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Trial
- Vaccine-educated T cells and a CD123 bispecific T-cell engager for treatment of acute myeloid leukemia.Blood advances · 2025Article
- From complexity to clarity: unravelling tumor heterogeneity through the lens of tumor microenvironment for innovative cancer therapy.Histochemistry and cell biology · 2024Review
- IL-7R licenses a population of epigenetically poised memory CD8Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Dual TCR-Expressing T Cells in Cancer: How Single-Cell Technologies Enable New Investigation.ImmunoHorizons · 2023Article
- Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy.Journal for immunotherapy of cancer · 2023Article
- Article
- What do cancer-specific T cells 'see'?Discovery immunology · 2023Review
- Cytotoxicity of WT1-reactive T cells against Wilms tumor: An implication for antigen-specific adoptive immunotherapy.BioImpacts : BI · 2023Article
- Systematic analysis of CD39, CD103, CD137, and PD-1 as biomarkers for naturally occurring tumor antigen-specific TILs.European journal of immunology · 2022Article
- Antigen-Specific TCR-T Cells for Acute Myeloid Leukemia: State of the Art and Challenges.Frontiers in oncology · 2022Review
- Potential biomarkers: Identifying powerful tumor specific T cells in adoptive cellular therapy.Frontiers in immunology · 2022Review
- Epitope spreading driven by the joint action of CART cells and pharmacological STING stimulation counteracts tumor escape via antigen-loss variants.Journal for immunotherapy of cancer · 2021Article
- The Anticancer Potential of T Cell Receptor-Engineered T Cells.Trends in cancer · 2021Review
- Special Review: The future of Immunotherapy.Immunotherapy advances · 2021Review
- Artificial T Cell Adaptor Molecule-Transduced TCR-T Cells Demonstrated Improved Proliferation Only When Transduced in a Higher Intensity.Molecular therapy oncolytics · 2020Article
- Review
- Virus-specific T cells for malignancies - then, now and where to?Current stem cell reports · 2020Article
- Targets and Antibody Formats for Immunotherapy of Neuroblastoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Review
- Current Perspectives in Cancer Immunotherapy.Cancers · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Although T cells genetically modified with chimeric antigen receptors became the first immune effector product to obtain FDA approval, T-cell products that recognize their antigenic targets through their native receptors have also produced encouraging responses. For instance, T cells recognizing immunogenic viral antigens are effective when infused in immunosuppressed patients. A large number of tumor antigens are also expressed on nonviral tumors, but these antigens are less immunogenic. Many tumors can evade a transferred immune response by producing variants, which have lost the targeted antigens, or inhibitory molecules that recruit suppressive cells, impeding persistence and function of immune effectors. Nevertheless, infusion of antigen-specific T cells has been well-tolerated, and clinical responses have been consistently associated with immune activity against tumor antigens and epitope spreading. To overcome some of the obstacles mentioned above, current research is focused on defining
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.